Orphan Drug Pricing and Costs: A Case Study of Kalydeco and Orkambi

Background: A common narrative is that high prices are necessary for "orphan drugs" because of the fewer patients. In the context of state health insurance systems, the high prices create significant challenges because of limited budgets. Results: This study carefully examines both costs a...

Full description

Saved in:
Bibliographic Details
Published in:Healthcare policy 2019-08, Vol.15 (1), p.70-80
Main Author: Hollis, Aidan
Format: Article
Language:English
Subjects:
Budgets
Case studies
Cystic fibrosis
Drug prices
Drugs
Health insurance
Power
Prices
R&D
Research & development
Research Paper
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: A common narrative is that high prices are necessary for "orphan drugs" because of the fewer patients. In the context of state health insurance systems, the high prices create significant challenges because of limited budgets. Results: This study carefully examines both costs and revenues of two drugs for cystic fibrosis (ivacaftor and lumacaftor), showing that, for this important example, prices are not high because of fewer patients. The study then explores the justifications usually given for high orphan drug prices, including the need to support research and development for new drugs. Each of these standard justifications is shown to be inadequate; instead, it appears that the exercise of market power in the presence of insurance is the dominant driver of high prices. Interpretation: Insurers need to re-examine how they address high-priced drugs.
ISSN:1715-6572
1715-6580
DOI:10.12927/hcpol.2019.25937